The China Diabetes Devices Market is expected to expand from US$ 7.19 billion in 2025 to US$ 14.51 billion by 2034, with a CAGR of 8.11% between 2026 and 2034. The factors that are driving the China Diabetes Devices Market are the growing prevalence of diabetes, awareness about managing the disease, infrastructure developments within the healthcare sector, and the adoption of glucose monitoring, insulin, and other devices.
China Diabetes care products have witnessed widespread acceptance in China owing to the exponentially rising diabetic population due to factors like an aging population, urbanization, lifestyle changes, and food habits. Education and awareness regarding timely diagnosis and self-testing have motivated people affected by diabetes to resort to home-care glucose monitoring systems. Government healthcare reforms, insurance policies, and increasing accessibility of healthcare products in China have contributed to this trend of acceptance of diabetes care products in China. The acceptance of healthcare technologies and affordable diabetes care products from China has strengthened acceptance in this vast diabetic patient population group in China.
China Diabetes Device Market Outlook
Diabetes care devices are medical devices which help patients monitor, control, and regulate their blood sugar levels effectively. These devices include blood glucose monitors, CGM devices, insulin pens, insulin pumps, and other accessory devices. These devices allow patients to track their blood sugar levels on a daily basis and help them administer insulin injections correctly in order to prevent complications such as cardio, kidney failure, and diabetic neuropathy. Technological advancements have enabled the evolution of diabetes management devices such as apps and alert systems.China Diabetes care products have witnessed widespread acceptance in China owing to the exponentially rising diabetic population due to factors like an aging population, urbanization, lifestyle changes, and food habits. Education and awareness regarding timely diagnosis and self-testing have motivated people affected by diabetes to resort to home-care glucose monitoring systems. Government healthcare reforms, insurance policies, and increasing accessibility of healthcare products in China have contributed to this trend of acceptance of diabetes care products in China. The acceptance of healthcare technologies and affordable diabetes care products from China has strengthened acceptance in this vast diabetic patient population group in China.
Growth Drivers of China Diabetes Devices Market
Rise in Prevalence of Diabetes and Older Population
The country that has the highest incidence of diabetes is China, with a total of over 118 million patients suffering from diabetes, contributing to 22% of the global diabetic population. The key fuelling element for the growth of the diabetes devices market for the Chinese region would be the rapidly rising incidence of this condition, helped by the country’s massive as well as ageing population. The change in lifestyle, as reflected by less exercise, a urban lifestyle, as well as consuming a lot of calories, has led to a substantial rise in the development of patients suffering from type 2 diabetes. Moreover, the ageing population of the Chinese region makes them increasingly prone to contracting chronic diseases such as diabetes, thus fuelling the demand for glucose, as well as insulin pens, for a long period of time in the Chinese region. The figures for the total ageing population of 60 years & above as well as 65 years & above by 2019 show 254 million & 176 million, respectively, indicating a sharp rise by the year 2040, estimating that 402 million, or 28%, would be over 60 years of age.Government Healthcare Reforms and Increased Access
Healthcare reforms and government investments help the market for diabetes devices in China grow rapidly. Extended coverage of public healthcare systems, improved insurance terms, and the inclusion of diabetes management products in the scope of insurance schemes make these products more affordable for consumers. Healthcare programs promoting early treatment, chronic management, and prevention of diseases support frequent glucose tests. Simultaneously, infrastructure improvements in lower-tier cities and rural areas are facilitating the development of healthcare infrastructure, readjusting the role of hospitals, and promoting home-based chronic management practices in terms of device adoption by the general population. In 2024, the National Reimbursement Drug List (NRDL) added 15 new drugs for diabetes, effective on the 1st of April, which automatically reduced the financial burden on people, promoting the adoption of supportive products Eric Ng, “China Expands Health Insurance Coverage. In the wake of the inclusion of Dorzagliatin, the revenue generated was 255.9 million RMB in 2024, increasing by 234% on an annually compounded basis in 2023 Hua Medicine, “Hua Medicine Announces 2024 Annual Results,” huamedicine.com. Capitation payment pilots started in rural counties, promoting better standards for the prescription of medications, pushing the financial incentives towards prevention.Technological Progress and Increased Domestic Production
Technological advancements are driving the adoption of sophisticated diabetes products in China. Continuous glucose monitoring systems, intelligent insulin pens, and smartphone-compatible glucose meters are quite accurate and easier to use. There is also a corresponding rise in the number of medical device companies in China, and as such, there are affordable options designed to meet local requirements. Digital health platform and smartphone application integration fits the robust digital infrastructure in China and promotes local patient participation and self-management. February 2023: Medtronic’s MiniMed 670G BLE hybrid closed-loop system was approved by the Chinese NMPA, adding electrochemical impedance sensing to optimize sensor performance.Challenges of the China Diabetes Devices Market
Cost Sensitivity and Incomplete Reimbursement Coverage
Although there has been progress, cost remains one factor that remains critical when it comes to the diabetic devices market in China. High-end technologies such as continuous glucose monitors and insulin pumps remain too costly for some patients, especially in remote areas with less economic development. The coverage by insurance also differs from one region to another, contributing to inequalities when it comes to access to high-end devices. Patients also have no choice but to depend on the basic glucose monitors due to cost sensitivity.Awareness gaps and patient compliance issues
The other significant issue is unequal awareness and patient compliance. In other areas, diabetic conditions remain underdiagnosed, and patients may fail to understand the significance of glucose level checks. The improper use of devices, lack of regular checks, and lack of follow-up services hamper the effectiveness of diabetic control. The problem, therefore, requires continuous patient education and the use of health support technology systems, which may be costly and difficult to roll out countrywide.China SMBG Devices Market
The self-monitoring of blood glucose (SMBG) devices market in China occupies a prominent position in the global market because of extensive usage and affordability. SMBG devices, such as glucose meters, test strips, and lancets, are typically used by diabetic patients for the regular checking of glucose levels. Because of their relative affordability and simplicity of use, the devices penetrate the rural and urban markets effectively. Government programs for increased diagnosis and checking also contribute to an increased demand for the devices. Despite the high level of competition, the devices continue to be relevant because of regular advancements in accuracy, carryability, and connectivity. The increasing number of diabetic patients also ensures that SMBG devices remain the backbone of diabetic patient care in ChinaChina CGM Devices Market
The market for continuous glucose monitoring systems in China is growing at a faster rate, thanks to the rising awareness levels among people about advanced diabetic management technologies. Continuous glucose monitors are capable of providing real-time glucose patterns, assisting patients and doctors to attain tighter glucose control. Continuous glucose monitors are widely accepted in China among people with type 1 diabetes and insulin-treated people with type 2 diabetes in urban China. The growing acceptance from people in urban China is expected to help the market attain steady growth in the coming years in China.China Insulin Pump Devices Market
China’s insulin pump devices market is gradually growing as people look for more accurate and flexible insulin infusion systems. Insulin pumps offer continuous subcutaneous insulin infusion, and they ensure better control of sugar and reduce the number of insulin injections to be taken by the body. Although the high cost and operational complexity of insulin pumps restrict the scale of their adoption, there has been increased use of intensive insulin therapy with growing awareness related to the severity of diabetes. Advances within the Chinese domestic environment will also play an essential role in the expansion of the insulin pumps consumption base and help the country’s insulin pumps market to demonstrate strong potential during the review period.China Insulin Pen Devices Market
Insulin pen injectors are in common practice in China because of their convenience, accuracy, and ease of use. The devices have shown better dose delivery compared to the syringe system, resulting in better patient compliance. Increased use of insulin therapy in type 2 diabetic patients is encouraging the market. Reusable and disposable pen injectors for insulin exist in the market, and Chinese companies have provided cheaper alternatives for the reusable type.China Diabetes Devices Hospital Pharmacies Market
Hospital-based pharmacies are very significant for the distribution of diabetes care products in the Chinese market. SMBG products, insulin pens, and other associated accessories are commonly distributed to customers when they visit hospitals. Highly persuasive doctor influence and trust in medical opinions help to enhance sales in this distribution channel. Government hospitals are significant in promoting the distribution of products on a large scale, especially through public healthcare programs.China Online Pharmacies Market for Diabetes Devices
Online pharmacies have become a growing type of distribution channel for diabetes devices in China. This has been facilitated by the rise of digitalization and the use of ecommerce. Patients can enjoy the benefits of convenient shopping, favorable pricing, and home delivery of glucose monitoring products as well as insulin devices. Additionally, the rise of online pharmacies will promote a subscription model of buying consumables like test strips and sensors. With the rise of digital healthcare platforms, the use of online pharmacies will increase in the diabetes devices industry.Beijing Diabetes Devices Market
The diabetes devices market in Beijing is fueled by its well-developed healthcare infrastructure, greater awareness of diabetes, and greater acceptance of new and innovative healthcare technologies. Being China’s capital, it is home to top-class healthcare institutions and diabetes treatment centers that promote new glucometers and insulin pens. The people of this city have greater acceptance of continuous glucose monitoring (CGM), insulin pens, and insulin pumps due to easier accessibility and recommendations from doctors and physicians. Support from China’s healthcare guidelines and insurance plans also helps people access diabetes devices. A highly developed digital healthcare sector of this city encourages acceptance of glucose monitoring devices that can be connected to mobile applications and work on new healthcare models of prevention and cure.Shanghai Diabetes Devices Market
Shanghai is also among the key and most dynamic markets in the Chinese diabetes monitors market, and the key reason for this is the high level of expenditure in the Chinese healthcare system, combined with the awareness of diabetes monitors and other diabetes-related products in the market. The advanced hospitals and private healthcare institutions in the city embrace state-of-the-art technology in diabetes monitors, CGM systems, and insulin pumps. In addition, the large geriatric population in the city and the growing lifestyle-related diabetic patients boost the demand for diabetic monitors in the Chinese market. As technology advances and patients turn to technology for diabetes management, the Chinese market, particularly the city of Shanghai, leads in the use of diabetes monitors.Tianjin Diabetes Devices Market
The competition in the diabetes care products market in the Tianjin region is rising due to increasing awareness and improving health infrastructure in the region. The hospitals and public health centers in Tianjin are important in the promotion of SMBG systems and insulin pens among the diabetic population in the region. Although the penetration of sophisticated technologies such as CGM systems and insulin pumps in the region remains in the growth stage, physician education and increasing urbanization are expected to contribute to increasing acceptance levels in the upcoming years. Government health programs focusing on early detection and monitoring are expected to support increasing demand in the region.Market Segmentation
Types
- Self-Monitoring Devices
- Continuous Glucose-Monitoring Devices
- Insulin Pumps
- Insulin Pens
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Diabetes Clinics/Centers
- Online Pharmacies
Top City
- Beijing
- Shanghai
- Jiangsu
- Fujian
- Zhejiang
- Tianjin
- Guangdong
- Inner Mongolia
- Hubei
- Chongqing
- Rest of China
All companies have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments
- SWOT Analysis
- Revenue Analysis
Company Analysis
- Roche
- Abbott Laboratories
- Novo Nordisk A/S
- BD
- Medtronic
- Eli Lilly
- Sanofi
Table of Contents
1. Introduction3. Executive Summary
2. Research & Methodology
4. Market Dynamics
5. China Diabetes Devices Market
6. China Diabetes Population
7. Market Share Analysis
8. Types
9. Distribution Channel
10. Cities
11. Porter’s Five Analysis
12. SWOT Analysis
13. Reimbursement Policies
14. Key Players Analysis
Companies Mentioned
The companies featured in this China Diabetes Devices market report include:- Roche
- Abbott Laboratories
- Novo Nordisk A/S
- BD
- Medtronic
- Eli Lilly
- Sanofi
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2026 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 7.19 Billion |
| Forecasted Market Value ( USD | $ 14.51 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | China |
| No. of Companies Mentioned | 8 |
